New review of current practice in use of LHRH receptor agonists and antagonists


The full text of a recent review on the use of LHRH receptor agonists (e.g., leuprolide acetate, goserelin acetate) asnd LHRH receptor antagonists (e.g., degarelix) has recently been published by Shore et al. in Prostate Cancer and Prostatic Diseases. The full text of the article is also available on line on the Medscape Oncology web site.

3 Responses

  1. Mike,

    Thanks this is very helpful.

    Bill

  2. Reading this article (and others) … has the time now come to change from the use of LHRH receptor agonists to antagonists? the only disadvantage seems to be mild injection-site reactions. If so, why doesn’t the oncological community decide on this policy?

  3. There is certainly a small cadre of specialists that would argue that this may be the case. On the other hand, the number of men who have actually been maintained for long periods of time on an LHRH antagonist is still small.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: